Supplementary Information Contains a List of the Relevant Abstracts Cited in This Article

SUPPLEMENTARY INFORMATION CONTAINS A LIST OF THE RELEVANT ABSTRACTS CITED IN THIS ARTICLE FROM THE EASL 2006, DDW 2006, AASLD 2005 and 2006 MEETINGS.

1Colombo M (Ed.; 2006) Abstracts of the 41st Annual Meeting of the European Association for the Study of the Liver: 2006 April 26–30; Vienna. J Hepatol 44 (Suppl 2): S3–S278

Taribavirin

Abstract 75. Benhamou Y et al. (2006) The safety and efficacy of viramidine plus pegylated interferon alfa-2a versus ribavirin plus pegylated interferon alfa-2b in therapy-naive patients infected with HCV: phase IIIresults. J Hepatol44: S273

Telaprevir

Abstract 12. Reesink HW et al. (2006) Initial results of a 14-day study of the hepatitis C virus inhibitor protease VX-950, in combination with peginterferon-alpha-2a. J Hepatol44: S272

Abstract 12. Kieffer T et al. (2006) Wild-yype HCV NS3 protease re-emerges during follow-up after 14 days of dosing with VX-950 in patients wtih genotype 1 HCV. J Hepatol44: S7

R1626

Abstract 731. Roberts S et al. (2006) Interim results of a multiple ascending dose study of R126, a novel nucleoside analog targeting HCV polymerase in chronic HCV patients. J Hepatol44:S269

2Blei AT (Ed.; 2006) Abstracts of the 57th annual meeting of the American Association for the Study of Liver Diseases (57th AASLD): 2006 October 27–31; Boston. Hepatology 44 (Suppl 1): S1–S258

Eltrombopag

Abstract LB3. McHutchison J et al. (2006) Eltrombopag, an oral platelet growth factor, facilitates initiation of interferon therapy in subjects with HCV associated thrombocytopenia: results from a phase II placebo controlled, double-blind, dose-ranging study

Albumin interferon

Abstract 1136. Nelson D et al. (2006) Sustained virologic response rates with albumin interferon alfa-2b in combination with ribavirin in non-responders to prior interferon therapy: interim results from a phase II study. Hepatology 44 (Suppl 1):A611

Abstract 1141. Zeuzem S et al. (2006) Interim (week 12) phase IIb virological efficacy and safety results of albumin interferon alpha-2b combined with ribavirin in genotype 1 chronic hepatitis C infection. J Hepatol44: S270

Telaprevir

Abstract 92. Kieffer T et al. (2006) Combination of telaprevir (VX-950) and PEG IFN alpha suppresses both wild-type virus and resistance variants in HCV genotype 1-infected patients in a 14 day phase 1b study. Hepatology 44(Suppl 1): A222

Abstract 927.Rodriguez-Torres M et al. (2006) Current status of subjects receiving peg-interferon-alfa-2A (PEG-IF) and ribavirin (RBV) follow-on therapy after 28-day treatment with the hepatitis C protease inhibitor teleaprevir (VX-950), PEG-IFN and RBV. Hepatology 44 (Suppl 1):A532

Abstract 1142. Forestier Net al. (2006) Current status of subjects receiving peg-interferon-alfa-2A (PEG-IFN) and ribavirin (RBV) after a 14-day study of the hepatitis C protease inhibitor telaprevir (VX-950) with PEG-IFN. Hepatology 44(Suppl 1):A614

Valopicitabine

Abstract 93. Lawitz E et al. (2006) Valopicitabine (NM283) plus PEG-interferon in treatment-naive hepatitis C patients with HCV genotype 1 infection: HCV RNA clearance during 24 weeks of treatment.Hepatology 44(Suppl 1):A223

ITMN-191

Abstract 933. Tan Het al. (2006) In vitro synergistic antiviral activity of ITMN-191, an orally active inhibitor of the hepatitis C virus (HCV) NS3/4A protease, in combination with PEG-interferon alfa-2a. Hepatology 44(Suppl 1):A534

CpG 10101

Abstract 96. Jacobson IM et al. (2006) Early viral response and on treatment response to CpG 10101 (Actilon), in combination with pegylated interferon and/or ribavirin, in chronic HCV genotype 1 infected patients with prior relapse response. Hepatology44(Suppl 1):A224

GI-5005

Abstract LB17. Everson GT et al. (2006) Interim results from a randomized, double-blind, placebo-controlled phase 1b study in subjects with chronic HCV after treatment with GI-5005, a yeast-based HCV immunotherapy targeting NS3 and core proteins. Hepatology 44:A697

4Blei AT (Ed.; 2005) Abstracts of the 56th annual meeting of the American Association for the Study of Liver Diseases (56th AASLD): 2005 November 11–15; San Francisco. Hepatology 42 (Suppl 1): S1–S257

Omega interferon

Abstract 1284. Gorbakov VV et al. (2005) HCV RNA results from a phase II, randomized, open-label study of omega interferon (IFN) with or without ribavirin in IFN-naive genotype 1 chronic HCV patients. Hepatology 42: A705

Telaprevir

Abstract 737. Reesink HW et al. (2005) Final results of a phase 1B, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor. Hepatology 42: A234-235

SCH 503034

Abstract 94. Zeuzem S et al. (2005) Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients refractory to pegylated interferon (Peg-IFN-). AASLD Hepatology 42: A233

Abstract 201. Zeuzem S et al. (2005) Combination therapy with the HCV protease inhibitor, SCH 503034, plus Peg-intron in hepatitis C genotype-1 Peg-intron non-responders: phase 1B results. Hepatology 42: A276-A277

NIM811

Abstract 866. Lin K et al. (2005) NIM811 exhibits potent anti-HCV activity in vitro and represents a novel approach for vial hepatitis C therapy. Hepatology A536

Valopicitabine

Abstract 4. Pockros P et al. (2006) Valopicitabine (NM283), alone or with peg-interferon, compared to peg-interferon/ribavirin (pegIFN/RBV) retreatment in hepatitis C patients with prior non-response to pegIFN/RBV: week 24 results. Gastro 130:A748

5Digestive Disease Week, May 21–24, 2006, Los Angeles, CA. Gastroenterology 5

Telaprevir

Abstract 96. Lawitz EJ et al. (2006) 28 days of the hepatitis C protease inhibitor VX-950, in combination with peg-interferon-alfa-2a and ribavirin, is well-tolerated and demonstrates robust antiviral effects. Abstract 686f. DDW